Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-411.88%
operating margin TTM
-412.58%
revenue TTM
1.95 Million
revenue per share TTM
0.13$
valuation ratios | |
|---|---|
| pe ratio | -2.88 |
| peg ratio | -0.03 |
| price to book ratio | 1.07 |
| price to sales ratio | 10.77 |
| enterprise value multiple | -6.10 |
| price fair value | 1.07 |
profitability ratios | |
|---|---|
| gross profit margin | 100.0% |
| operating profit margin | -412.58% |
| pretax profit margin | -412.64% |
| net profit margin | -411.88% |
| return on assets | -27.55% |
| return on equity | -36.99% |
| return on capital employed | -32.47% |
liquidity ratios | |
|---|---|
| current ratio | 6.53 |
| quick ratio | 6.53 |
| cash ratio | 6.46 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 0.00 |
| cash conversion cycle | 0.00 |
| receivables turnover | 0.00 |
| payables turnover | 0.00 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -11.20 |
cash flow ratios | |
|---|---|
| free cash flow per share | -2.49 |
| cash per share | 15.78 |
| operating cash flow per share | -2.40 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -11.20 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -28.46 |
Frequently Asked Questions
When was the last time Atrium Therapeutics, Inc. (NASDAQ:RNA) reported earnings?
Atrium Therapeutics, Inc. (RNA) published its most recent earnings results on 10-11-2025.
What is Atrium Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Atrium Therapeutics, Inc. (NASDAQ:RNA)'s trailing twelve months ROE is -36.99%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Atrium Therapeutics, Inc. (RNA) currently has a ROA of -27.55%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did RNA's net profit margin stand at?
RNA reported a profit margin of -411.88% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is RNA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.53 in the most recent quarter. The quick ratio stood at 6.53, with a Debt/Eq ratio of 0.02.